Both in vitro and in vivo studies show that aberrant expression of lnc‐Ip53, which is frequently observed in hepatocellular carcinoma (HCC) and other cancer types, promotes tumor growth and chemoresistance by inhibiting p53 acetylation/activity. This evidence concerns the gene TP53 and hepatocellular carcinoma.